HOME > About Walvax > Research and Development (R&D center)

  The Research and Development Center (R&D center) of Walvax Biotechnology Co., Ltd. is located in High-tech zone of Kunming, and it covers an area of 2100 m2. The R&D center integrates advanced technologies and facilities, innovative people and other R&D related technological resource together. The R&D center has ten departments, including Detection Technology and Standard Research Laboratory, Chemical Coupling and Virus Research Laboratory and so on. These departments established platforms for the research and development of bacteria vaccine, virus vaccine, genetic engineering vaccine, new adjuvant vaccine, combined vaccine and other kinds of vaccine. The R&D center has a wealth of experience on conjugating protein to bacterial polysaccharide, large scale fermentation, bacterial polysaccharide purification, bacterial endotoxin removal, virus separation, seed bank establishment, viral vaccine antigen purification and many other core R&D technologies related to vaccine.
  Walvax has been focusing on vaccine development. On the basis of deep understanding of vaccine industrial chain and keen insight into the market, Walvax takes market demand oriented, upgrading product and filling in the gaps of domestic market as the main strategy. By adopting a matrix method to make full use of  it's R&D resource. Walvax has successfully developed Haemophilus influenza Type b Conjugate Vaccine (Hib) and Group A, C Meningococcal Polysaccharide Conjugate Vaccine and other twelve vaccine products. Meanwhile, the R&D center has established an open operation mechanism mode of sharing technology resource and R&D collaboration. Walvax aims to optimize the resource allocation and improve the efficiency and benefit of technology innovation according to the demands of the market.